Related references
Note: Only part of the references are listed.A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer
Zhefeng Liu et al.
MEDICAL ONCOLOGY (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Patient-Reported Neuropathy and Taxane-Associated Symptoms in a Phase 3 Trial of nab-Paclitaxel Plus Carboplatin versus Solvent-Based Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer
Vera Hirsh et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer
M. A. Socinski et al.
ANNALS OF ONCOLOGY (2013)
Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer
M. A. Socinski et al.
ANNALS OF ONCOLOGY (2013)
Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years
Tanja Cufer et al.
EUROPEAN JOURNAL OF CANCER (2013)
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
A phase 2 study of weekly albumin-bound paclitaxel (AbraxaneA®) given as a two-hour infusion
Paul K. Paik et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Phase I and Pharmacokinetic Study of ABI-007, Albumin-bound Paclitaxel, Administered Every 3 Weeks in Japanese Patients with Solid Tumors
Kazuhiko Yamada et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer A National Cancer Database Survey
Daniel Morgensztern et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer
Craig Reynolds et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer
Naiyer A. Rizvi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies
Thomas E. Stinchcombe et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer
M. R. Green et al.
ANNALS OF ONCOLOGY (2006)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
WJ Gradishar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation
H Gelderblom et al.
EUROPEAN JOURNAL OF CANCER (2001)
Share Paper
